Extended-release Naltrexone for Alcohol and Opioid Dependence: A Meta-Analysis of Healthcare Utilization Studies Public Deposited

http://ir.library.oregonstate.edu/concern/articles/mk61rj63x

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over six months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Hartung, D. M., McCarty, D., Fu, R., Wiest, K., Chalk, M. & Gastfriend, D. R. (2014). Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. Journal of Substance Abuse Treatment, 47(2), 113-121. doi: 10.1016/j.jsat.2014.03.007
Series
Keyword
Rights Statement
Funding Statement (additional comments about funding)
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Submitted by Sue Kunda (sue.kunda@oregonstate.edu) on 2014-04-18T23:51:38Z No. of bitstreams: 1 HartungPharmacyExtendedReleaseNaltrexone.pdf: 1451333 bytes, checksum: 896d89f238d704398a84ecb198ad212d (MD5)
  • description.provenance : Approved for entry into archive by Sue Kunda(sue.kunda@oregonstate.edu) on 2014-04-18T23:52:14Z (GMT) No. of bitstreams: 1 HartungPharmacyExtendedReleaseNaltrexone.pdf: 1451333 bytes, checksum: 896d89f238d704398a84ecb198ad212d (MD5)
  • description.provenance : Made available in DSpace on 2014-04-18T23:52:15Z (GMT). No. of bitstreams: 1 HartungPharmacyExtendedReleaseNaltrexone.pdf: 1451333 bytes, checksum: 896d89f238d704398a84ecb198ad212d (MD5) Previous issue date: 2014

Relationships

In Administrative Set:
Last modified: 07/26/2017

Downloadable Content

Download PDF
Citations:

EndNote | Zotero | Mendeley

Items